Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | CA2 | P00918 | 4/20 | 0.38 |
| ▸ | CA12 | O43570 | 3/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.33 |
| ▸ | MLYCD | O95822 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20326558 | 0.87 | CA1 (0.45) | CA1CA2CA12CA9CA14 | |
| SCHEMBL31407675 | 0.86 | CA14 (0.37) | CA1CA2CA12CA14HDAC6 | |
| SCHEMBL78691 | 0.85 | CA14 (0.41) | CA14HDAC6HDAC1HDAC2CTSL | |
| SCHEMBL883067 | 0.83 | CA2 (0.39) | CA1CA2CA12CA9CA14 | |
| SCHEMBL27035589 | 0.83 | CA14 (0.40) | CA1CA2CA12CA9CA14 | |
| SCHEMBL29865442 | 0.83 | CA14 (0.34) | CA1CA2CA12CA14HDAC6 | |
| SCHEMBL18829766 | 0.82 | CA14 (0.35) | CA14HDAC6HDAC1HDAC2 | |
| SCHEMBL18829247 | 0.82 | CA14 (0.32) | CA14 | |
| SCHEMBL20663579 | 0.82 | CA14 (0.32) | CA14 | |
| SCHEMBL18465661 | 0.82 | CA14 (0.35) | CA1CA2CA12CA14HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612407-B2 | Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist | BEONE MEDICINES I GMBH (CH) | 2026-04-28 | — | — | US | disclosed |
| CN-113423708-B | Imidazo [2,1-F ] [1,2,4] triazin-4-amine derivatives as TLR7 agonists | 百济神州有限公司 | 2025-04-22 | — | — | CN | disclosed |
| EP-3921319-B1 | IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | BEIGENE LTD (KY) | 2024-03-06 | — | — | EP | disclosed |
| US-20230167117-A1 | IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | BEONE MEDICINES I GMBH (CH) | 2023-06-01 | — | — | US | disclosed |
| EP-3921319-A1 | IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | BeiGene, Ltd. (KY) | 2021-12-15 | — | — | EP | disclosed |
| CN-113423708-A | Imidazo [2,1-F ] [1,2,4] triazin-4-amine derivatives as TLR7 agonists | 百济神州有限公司 | 2021-09-21 | — | — | CN | disclosed |
| EP-3699176-A2 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2020-08-26 | — | — | EP | disclosed |
| WO-2020160710-A1 | IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | BEIGENE, LTD. (KY) | 2020-08-13 | — | — | WO | disclosed |
| EP-3284741-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2018-02-21 | — | — | EP | disclosed |
| US-8278329-B2 | Antagonizing N-type calcium channels; use as analgesic, neurodegenerative diseases, brain injury, bronchial asthma, unstable angina and irritable colitis, drug withdrawal symptoms; t-butyl 2-[4-(5H-dibenzo[a,d][7]annulen-5-ylidene)-1-piperidinyl]-2-oxoethylcarbamate for example | AJINOMOTO CO., INC. (JP) | 2012-10-02 | — | — | US | disclosed |
| US-7384933-B2 | Derivatives of 2-hydroxytetrahydrofuran and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2008-06-10 | — | — | US | disclosed |
| EP-1701974-B1 | NOVEL 2-HYDROXYTETRAHYDROFURANE DERIVATIVES AND USE THEREOF AS MEDICAMENTS | SOD CONSEILS RECH APPLIC (FR) | 2008-03-26 | — | — | EP | disclosed |
| US-20080058311-A1 | NOVEL DIARYLALKENE DERIVATIVES AND NOVEL DIARYLALKANE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2008-03-06 | — | — | US | disclosed |
| EP-1701974-A2 | NOVEL 2-HYDROXYTETRAHYDROFURANE DERIVATIVES AND USE THEREOF AS MEDICAMENTS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2006-09-20 | — | — | EP | disclosed |
| US-20060166893-A1 | Novel 2-hydroxytetrahydrofurane derivatives and use thereof as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (FR) | 2006-07-27 | — | — | US | disclosed |
| US-20050222045-A1 | Novel derivatives of 2-hydroxytetrahydrofuran and their use as medicaments | IPSEN PHARMA S.A.S. (FR) | 2005-10-06 | — | — | US | disclosed |
| WO-2005056551-A2 | NOVEL 2-HYDROXYTETRAHYDROFURANE DERIVATIVES AND USE THEREOF AS MEDICAMENTS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2005-06-23 | — | — | WO | disclosed |
| US-20050009814-A1 | Pharmaceutical composition containing gabapentin or pregabalin and N-type calcium channel antagonist | AJINOMOTO CO., INC. (JP) | 2005-01-13 | — | — | US | disclosed |
| EP-1481673-A1 | MEDICINAL COMPOSITIONS CONTAINING GABAPENTIN OR PREGABALIN AND N-TYPE CALCIUM CHANNEL ANTAGONIST | Ajinomoto Co., Inc. (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-20040167118-A1 | Novel diarylalkene derivatives and novel diarylalkane derivatives | AJINOMOTO CO., INC. (JP) | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166893-A1 | Novel 2-hydroxytetrahydrofurane derivatives and use thereof as medicaments | CAPN2, CAPN1, CAPNS1 | CA1 2096/4885CA2 755/4885CA12 3603/4885 |
| US-20050009814-A1 | Pharmaceutical composition containing gabapentin or pregabalin and N-type calcium channel antagonist | CACNA1B, CACNA1G, CACNA1C | CA1 807/4885CA2 114/4885CA12 1852/4885 |
| US-20050222045-A1 | Novel derivatives of 2-hydroxytetrahydrofuran and their use as medicaments | CAPN1, MYH10, CAPN9 | CA1 2338/4885CA2 941/4885CA12 2318/4885 |
| US-20230167117-A1 | IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | TLR7, TLR1, TLR9 | CA1 4618/4885CA2 2199/4885CA12 4401/4885 |
| US-12612407-B2 | Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist | TLR7, TLR8, TLR1 | CA1 4356/4885CA2 1977/4885CA12 4390/4885 |
| US-20040167118-A1 | Novel diarylalkene derivatives and novel diarylalkane derivatives | CACNA1E, CACNA1H, CACNA1D | CA1 1110/4885CA2 135/4885CA12 1326/4885 |
| US-20080058311-A1 | NOVEL DIARYLALKENE DERIVATIVES AND NOVEL DIARYLALKANE DERIVATIVES | CACNA1E, CACNA1D, CACNA1H | CA1 972/4885CA2 118/4885CA12 1106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.